Breakfast Technical Briefing on Biotech Stocks -- Kite Pharma, Novavax, Sangamo Therapeutics, and Spectrum Pharma
21 Aug, 2017, 06:10 ET
NEW YORK, August 21, 2017 /PRNewswire/ --
If you want a Stock Review on KITE, NVAX, SGMO, or SPPI then come over to http://dailystocktracker.com/register/ and sign up for your free customized report today. Today, DailyStockTracker.com highlights the performances of Kite Pharma Inc. (NASDAQ: KITE), Novavax Inc. (NASDAQ: NVAX), Sangamo Therapeutics Inc. (NASDAQ: SGMO), and Spectrum Pharmaceuticals Inc. (NASDAQ: SPPI). These stocks belong to the Biotech industry, which consists of companies engaged in the research and development of new drugs, medical devices, and procedures. The space includes the manufacturing and marketing of drugs as a result of direct research and development. Daily Stock Tracker published free research reports on these stocks today at:
Santa Monica, California headquartered Kite Pharma Inc.'s stock rose 3.29%, finishing last Friday's trading session at $130.18. A total volume of 1.06 million shares was traded. The Company's shares have surged 18.46% in the last month, 84.10% over the previous three months, and 190.32% since the start of this year. The stock is trading above its 50-day and 200-day moving averages by 23.73% and 77.32%, respectively. Additionally, shares of Kite Pharma, which focuses on the development and commercialization of novel cancer immunotherapy products, have a Relative Strength Index (RSI) of 77.00.
On August 07th, 2017, Kite Pharma announced that patients in the European Union (EU) are now being treated with its lead investigational candidate, axicabtagene ciloleucel, in the safety expansion cohort of ZUMA-1 (ClinicalTrials.gov, NCT: 02348216). The Company is currently enrolling adult patients with relapsed/refractory diffuse large B-cell lymphoma, primary mediastinal B-cell lymphoma, and transformed follicular lymphoma at multiple EU medical centers. See our free and comprehensive research report on KITE at:
Shares in Gaithersburg, Maryland headquartered Novavax Inc. ended at $1.00, climbing 1.05% from the last trading session. The stock recorded a trading volume of 2.72 million shares. The Company's shares are trading 10.86% below their 50-day moving average. Moreover, shares of Novavax, which focuses on the discovery, development, and commercialization of recombinant nanoparticle vaccines and adjuvants, have an RSI of 43.12.
On August 08th, 2017, Novavax announced its financial results for Q2 ended June 30th, 2017. In Q2 2017, revenue was $6.7 million; net loss was $44.5 million; R&D expenses were $39.3 million; and G&A expenses were $8.9 million. As of June 30th, 2017, the Company had $187.3 million in cash and cash equivalents and marketable securities.
On August 09th, 2017, research firm Ladenburg Thalmann upgraded the Company's stock rating from 'Neutral' to 'Buy'. NVAX free research report is just a click away at:
On Friday, shares in Richmond, California headquartered Sangamo Therapeutics Inc. recorded a trading volume of 1.67 million shares, which was above their three months average volume of 1.33 million shares. The stock dropped 3.41%, closing the day at $9.90. The Company's shares have gained 3.66% in the last one month, 26.92% over the previous three months, and 224.59% on an YTD basis. The stock is trading 10.78% above its 50-day moving average and 79.25% above its 200-day moving average. Additionally, shares of Sangamo Therapeutics have an RSI of 54.73.
On August 09th, 2017, Sangamo Therapeutics reported its Q2 2017 financial results. Consolidated net loss for the quarter ended June 30th, 2017 was $12.5 million, and revenues were $8.3 million. R&D expenses for Q2 2017 were $15.0 million, G&A expenses were $6.0 million, and total operating expenses were $21.0 million. Sign up for your complimentary report on SGMO at:
At the close of trading on Friday, shares in Henderson, Nevada headquartered Spectrum Pharmaceuticals Inc. recorded a trading volume of 1.17 million shares, which was higher than their three months average volume of 792,550 shares. The stock finished the session 0.53% lower at $9.40. The Company's shares have surged 16.92% in the past month, 63.48% in the previous three months, and 112.19% since the start of this year. The stock is trading above its 50-day and 200-day moving averages by 22.11% and 56.37%, respectively. Furthermore, shares of Spectrum Pharma, which develops and commercializes oncology and hematology drug products, have an RSI of 68.45.
On August 16th, 2017, research firm H.C. Wainwright resumed its 'Buy' rating on the Company's stock, with a target price of $14 per share.
On August 17th, 2017, Spectrum Pharma announced that an overview of its business strategy and commercial and development-stage programs will be given at the 2017 Southern California Investor Conference being held at The Island Hotel in Newport Beach, California. The Company presentation is on August 24th, 2017, at 9:30 a.m. PT. Register for free on DailyStockTracker.com and download the latest research report on SPPI at:
Daily Stock Tracker:
Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
DST has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: [email protected]
Phone number: (207) 331-3313
Office Address: 377 Rivonia Boulevard, Rivonia, South Africa
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA
Share this article